Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1946 1
1951 2
1955 2
1956 1
1962 1
1964 1
1965 1
1970 1
1975 1
1976 1
1977 1
1979 1
1980 1
1981 6
1982 2
1984 3
1985 3
1986 6
1987 4
1988 7
1989 5
1990 12
1991 6
1992 8
1993 12
1994 17
1995 13
1996 15
1997 19
1998 25
1999 12
2000 20
2001 20
2002 23
2003 20
2004 28
2005 23
2006 31
2007 37
2008 45
2009 47
2010 39
2011 69
2012 58
2013 57
2014 67
2015 89
2016 97
2017 71
2018 104
2019 108
2020 102
2021 115
2022 127
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

1,380 results
Results by year
Filters applied: . Clear all
Page 1
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Paganoni S, et al. Among authors: quinn c. N Engl J Med. 2020 Sep 3;383(10):919-930. doi: 10.1056/NEJMoa1916945. N Engl J Med. 2020. PMID: 32877582 Free PMC article. Clinical Trial.
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson TD, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Hall M, Kittle G, Eydinov M, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, St Pierre ME, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Yu ZF, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Paganoni S, et al. Among authors: quinn c. Muscle Nerve. 2021 Jan;63(1):31-39. doi: 10.1002/mus.27091. Epub 2020 Oct 30. Muscle Nerve. 2021. PMID: 33063909 Free PMC article. Clinical Trial.
Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis.
Cserni G, Quinn CM, Foschini MP, Bianchi S, Callagy G, Chmielik E, Decker T, Fend F, Kovács A, van Diest PJ, Ellis IO, Rakha E, Tot T, European Working Group For Breast Screening Pathology. Cserni G, et al. Among authors: quinn cm. Cancers (Basel). 2021 Nov 14;13(22):5694. doi: 10.3390/cancers13225694. Cancers (Basel). 2021. PMID: 34830849 Free PMC article. Review.
Apocrine lesions of the breast.
Quinn CM, D'Arcy C, Wells C. Quinn CM, et al. Virchows Arch. 2022 Jan;480(1):177-189. doi: 10.1007/s00428-021-03185-4. Epub 2021 Sep 18. Virchows Arch. 2022. PMID: 34537861 Free PMC article. Review.
Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines.
Schünemann HJ, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi PG, Lebeau A, Nyström L, Broeders M, Ioannidou-Mouzaka L, Duffy SW, Borisch B, Fitzpatrick P, Hofvind S, Castells X, Giordano L, Canelo-Aybar C, Warman S, Mansel R, Sardanelli F, Parmelli E, Gräwingholt A, Saz-Parkinson Z; European Commission Initiative on Breast Cancer (ECIBC) Contributor Group. Schünemann HJ, et al. Among authors: quinn c. Ann Intern Med. 2020 Jan 7;172(1):46-56. doi: 10.7326/M19-2125. Epub 2019 Nov 26. Ann Intern Med. 2020. PMID: 31766052 Free article.
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group. Gonzalez-Ericsson PI, et al. Among authors: quinn c. J Pathol. 2020 Apr;250(5):667-684. doi: 10.1002/path.5406. Epub 2020 Apr 9. J Pathol. 2020. PMID: 32129476 Free article. Review.
1,380 results